WallStSmart

AstraZeneca PLC (AZN)vsOrthopediatrics Corp (KIDS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 24753% more annual revenue ($58.74B vs $236.35M). AZN leads profitability with a 17.4% profit margin vs -16.8%. AZN earns a higher WallStSmart Score of 64/100 (C+).

AZN

Buy

64

out of 100

Grade: C+

Growth: 6.7Profit: 8.0Value: 5.3Quality: 5.0
Piotroski: 6/9Altman Z: 1.48

KIDS

Hold

38

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZNUndervalued (+4.1%)

Margin of Safety

+4.1%

Fair Value

$214.51

Current Price

$187.37

$27.14 discount

UndervaluedFair: $214.51Overvalued
KIDSUndervalued (+76.8%)

Margin of Safety

+76.8%

Fair Value

$74.10

Current Price

$15.06

$59.04 discount

UndervaluedFair: $74.10Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZN5 strengths · Avg: 9.0/10
Market CapQuality
$287.11B10/10

Mega-cap, among the largest globally

EPS GrowthGrowth
53.9%10/10

Earnings expanding 53.9% YoY

Return on EquityProfitability
22.8%9/10

Every $100 of equity generates 23 in profit

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$1.38B8/10

Generating 1.4B in free cash flow

KIDS2 strengths · Avg: 9.0/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
17.0%8/10

17.0% revenue growth

Areas to Watch

AZN4 concerns · Avg: 3.5/10
PEG RatioValuation
1.544/10

Expensive relative to growth rate

P/E RatioValuation
27.9x4/10

Moderate valuation

Revenue GrowthGrowth
4.1%4/10

4.1% revenue growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

KIDS4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$406.36M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-11.3%2/10

ROE of -11.3% — below average capital efficiency

Profit MarginProfitability
-16.8%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.

Bull Case : KIDS

The strongest argument for KIDS centers on Price/Book, Revenue Growth. Revenue growth of 17.0% demonstrates continued momentum.

Bear Case : AZN

The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : KIDS

The primary concerns for KIDS are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

AZN profiles as a value stock while KIDS is a growth play — different risk/reward profiles.

KIDS carries more volatility with a beta of 1.16 — expect wider price swings.

KIDS is growing revenue faster at 17.0% — sustainability is the question.

AZN generates stronger free cash flow (1.4B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (64/100 vs 38/100), backed by strong 17.4% margins. KIDS offers better value entry with a 76.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Orthopediatrics Corp

HEALTHCARE · MEDICAL DEVICES · USA

OrthoPediatrics Corp. The company is headquartered in Warsaw, Indiana.

Want to dig deeper into these stocks?